Fatty Liver (NAFLD): The Supplements With Real Evidence

The Evidence on Supplements for Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) affects roughly 25% of the global population and is now the most common chronic liver condition worldwide. It ranges from simple steatosis (fat accumulation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and can progress to fibrosis and cirrhosis.

There is currently no FDA-approved drug for NAFLD. This has driven enormous interest in supplements — some with genuine clinical support, others with more marketing than evidence.

The Elephant in the Room: Weight Loss

Before discussing supplements, one fact must be stated clearly: weight loss of just 5–10% of body weight is more effective than any supplement for NAFLD. A 2019 meta-analysis in Hepatology showed that 7% weight loss resolved NASH in 65% of patients and improved fibrosis in 45%.

Supplements can complement lifestyle changes. They cannot replace them.

Tier 1: Strong Evidence

Omega-3 Fatty Acids

Dose: 2,000–4,000 mg combined EPA+DHA daily Evidence strength: Strong

Omega-3s are the most studied supplement for NAFLD. A 2018 Cochrane review analysing 18 RCTs concluded that omega-3 supplementation significantly reduces liver fat content as measured by imaging. A 2020 meta-analysis in Clinical Nutrition (28 RCTs, n=1,682) confirmed significant reductions in liver fat, triglycerides, and ALT levels.

The key is therapeutic dosing. Standard fish oil capsules provide 300–500 mg EPA+DHA per capsule. You typically need 4–8 capsules daily to reach the 2,000–4,000 mg range used in trials. Concentrated formulations (such as Nordic Naturals Ultimate Omega 2X) provide higher amounts per capsule.

Important: Omega-3 at these doses has mild blood-thinning effects. Inform your doctor if you take anticoagulants.

Vitamin E

Dose: 400–800 IU/day (as alpha-tocopherol) Evidence strength: Strong for NASH

The landmark PIVENS trial (New England Journal of Medicine, 2010) found 800 IU/day vitamin E improved liver histology in 43% of NASH patients vs. 19% on placebo (p=0.001). This was a large, well-designed, multicentre RCT that changed clinical practice.

Current AASLD guidelines recommend vitamin E (800 IU/day) for non-diabetic adults with biopsy-confirmed NASH. It is not recommended for NAFLD without NASH, diabetic NASH, or NASH without biopsy confirmation.

Safety note: Long-term high-dose vitamin E (>400 IU) has been associated with slightly increased all-cause mortality in some meta-analyses, though this remains debated. Do not self-prescribe — discuss with your hepatologist.

Tier 2: Moderate Evidence

Milk Thistle (Silymarin)

Dose: 420–600 mg standardised silymarin daily Evidence strength: Moderate

Silymarin has antioxidant, anti-inflammatory, and antifibrotic properties demonstrated in cell and animal models. A 2017 meta-analysis in Alimentary Pharmacology & Therapeutics (8 RCTs) found silymarin significantly reduced ALT and AST levels in NAFLD patients.

However, the evidence is limited by small sample sizes and heterogeneous study designs. Silymarin is unlikely to harm and may provide modest hepatoprotective benefit, but it should not be considered a primary treatment for NAFLD.

NAC (N-Acetyl Cysteine)

Dose: 600–1,200 mg/day Evidence strength: Moderate

NAC is a precursor to glutathione, the liver's primary endogenous antioxidant. NAFLD patients typically have depleted glutathione levels. A 2018 RCT in Hepatitis Monthly found NAC supplementation (1,200 mg/day for 12 weeks) improved liver enzymes and ultrasound findings. Evidence is promising but requires larger confirmatory trials.

Berberine

Dose: 500 mg 2–3 times daily Evidence strength: Moderate

Berberine is a plant alkaloid that improves insulin sensitivity and lipid metabolism — two central drivers of NAFLD. A 2013 RCT in the World Journal of Gastroenterology found berberine (500 mg three times daily for 16 weeks) reduced liver fat content by 52% on ultrasound.

Berberine also reduces HbA1c and LDL cholesterol, making it particularly useful in NAFLD patients with metabolic syndrome. Note: berberine can interact with several medications — check with your pharmacist.

What Liver Enzymes Do and Don't Tell You

Elevated ALT and AST suggest liver inflammation, but normal enzymes do not exclude significant fatty liver disease. Up to 25% of NAFLD patients with fibrosis have normal ALT. Conversely, mildly elevated enzymes may not indicate serious damage.

The gold standard for assessing NAFLD severity is:

• FibroScan (transient elastography) — non-invasive stiffness measurement
• MRI-PDFF — precise liver fat quantification
• Liver biopsy — definitive but invasive, reserved for unclear cases

If you have risk factors (obesity, type 2 diabetes, metabolic syndrome), request imaging assessment rather than relying on blood tests alone.

A Practical NAFLD Support Protocol

1. Lifestyle first: Target 5–10% weight loss through sustainable dietary changes and regular exercise
2. Omega-3: 2,000–4,000 mg EPA+DHA daily with food
3. Milk thistle: 420 mg standardised silymarin daily
4. NAC: 600 mg twice daily on an empty stomach
5. If NASH confirmed: Discuss vitamin E 800 IU/day with your hepatologist
6. If metabolic syndrome present: Consider berberine 500 mg twice daily

Monitor progress with FibroScan or liver imaging every 6–12 months, not just blood tests.

Ready for Your Personalized Protocol?

Every body is different. What works for one person may not work for another. Our free 5-minute assessment analyzes your health profile, medications, and goals to create an evidence-based supplement plan tailored specifically to you.

Take the free assessment →